Expert perspectives on biosimilar monoclonal antibodies in breast cancer

Breast Cancer Research and Treatment

Volumn 144, Issue 2, 2014, Pages 233-239

  Cortes J ^a   Curigliano, G ^b   Dieras V ^c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c INSTITUT CURIE   (France)

Author keywords

Biosimilar antibody; Breast cancer; CT P6; Extrapolation; Herceptin ; Trastuzumab

Indexed keywords

ABP 90; BCD 022; BIOSIMILAR MONOCLONAL ANTIBODY; CT P 6; INFLIXIMAB; MONOCLONAL ANTIBODY; PF 05280014; TRASTUZUMAB; UNCLASSIFIED DRUG; BIOSIMILAR AGENT;

BREAST CANCER; CLINICAL TRIAL (TOPIC); DRUG LABELING; EUROPE; EXTRAPOLATION; HUMAN; INTERCHANGEABILITY; ONCOLOGY; PARAMETERS; PRIORITY JOURNAL; REVIEW; SUBSTITUTION; SWITCHING; BREAST NEOPLASMS; FEMALE;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS;

EID: 84896549088     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2879-9     Document Type: Review

References (39)

1. Slamon DJ, Leyland-Jones B, Shak S et al (2009) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
2. Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373
3. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, Herceptin Adjuvant (HERA) Trial Study Team et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomized controlled trial. Lancet 382:1021-1028
4. Revers L, Furczon E (2010) An introduction to biologics and biosimilars. Part II: Subsequent entry biologics: biosame or biodifferent? Can Pharm J 143:184-191
5. Weise M, Bielsky MC, De Smet K et al (2011) Biosimilars-why terminology matters. Nat Biotechnol 29:691-693
6. Carey K (2011) Biosimilars encircle Rituxan, US debates innovator exclusivity. Nat Biotechnol 29:177-178
7. European Medicines Agency (2013) European public assessment reports: Biosimilars. http://www.ema.europa.eu/ema/index.jsp?curl= pages%2Fmedicines%2Flanding%2Fepar-search.jsp&mid=WC0b01ac058001d125& searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery= true&status=Authorised&status=Withdrawn&status=Suspended&status= Refused&keyword=Enter?keywords&searchType=name&taxonomyPath= &treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch= Submit. Accessed Nov 2013
8. Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. London, United Kingdom: Committee for Medicinal Products for Human Use, European Medicines Agency 2012
9. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. London, United Kingdom: Committee for Medicinal Products for Human Use, European Medicines Agency 2012
10. Im Y-H, Krasnozhon D, Bondarenko I, et al. (2013) Phase I/IIb clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6. Presented at the St Gallen Breast Cancer Conference 13-16 March 2013 in St. Gallen, Switzerland. Abstract 268
11. Im Y-H, Odarchenko P, Grecea D, et al. (2013) Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer as first-line treatment. J Clin Oncol 31: Poster 629
12. Celltrion files for approval of CT-P6, breast cancer mAb biosimilar, in Korea. Incheon, Korea: Celltrion, Inc; 4 June 2013. http://www.celltrion.com/en/ COMPANY/notice-view.asp?idx=348&code=ennews. Accessed Nov 2013
13. Yin D, Barker KB, Ruifeng L, et al. (2013) A phase I pharmacokinetics trial comparing PF-05280014 (a potential biosimilar) and trastuzumab in healthy volunteers (REFLECTIONS B327-01). J Clin Oncol 31: Abstract 612
14. Ewesuedo R, Barker KB, Taylor CT, Jacobs I (2013) A phase 3 randomized, double-blind trial comparing PF-05280014 + paclitaxel vs trastuzumab + paclitaxel for treatment of HER2 + metastatic breast cancer. Cancer Res 73 (24 Suppl): Abstract OT1-1-03
15. Clinical Trials.gov (Internet). Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - Identifier NCT01084876, Demonstrate efficacy and safety of metastatic breast cancer (COMPARE); 9 March 2010. http:// clinicaltrials.gov/ct2/show/NCT01084876. Accessed Dec 2013
16. PBR (Web site). Biocon may launch Roche's Herceptin biosimilar version by March 2014. http://drugdiscovery.pharmaceutical-business-review.com/news/ biocon-may-launch-roches-herceptin-biosimilar-version-by-March-2014-220813. Accessed Nov 2013
17. Clinical Trials.gov (Internet). Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - Identifier NCT01764022, A safety and efficacy study of BCD-022 with paclitaxel compared to herceptin with paclitaxel in HER2-positive metastatic breast cancer patients; 7 January 2013. http://clinicaltrials.gov/ct2/show/NCT01764022. Accessed Dec 2013
18. Clinical Trials.gov (Internet). Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - Identifier NCT01901146, Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac); 20 May 2013. http://clinicaltrials.gov/ct2/show/NCT01901146. Accessed Dec 2013
19. Tsavaris N, Kosmas C, Vadiaka M et al (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87:21-27
20. Standish LJ, Torkelson C, Hamill FA et al (2008) Immune defects in breast cancer patients after radiotherapy. J Soc Integr Oncol 6:110-121
21. Saso R, Kulkarni S, Mitchell P et al (2000) Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 83:91-94 (Pubitemid 30352723)
22. Smith RE (2003) Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer 4:273-279
23. Hotta K, Kiura K, Fujiwara Y et al (2009) Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann Oncol 20:829-834
24. Lee L, Wang L, Crump M (2011) Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol 22:1392-1403
25. Von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-1804
26. European Medicines Agency (2013) European public assessment reports: Remsima. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/002576/human-med-001682.jsp. Accessed Nov 2013
27. European Medicines Agency. European public assessment reports: Inflectra. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002778/human-med-001677.jsp. Accessed Nov 2013
28. Vu T, Claret FX (2012) Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2:62
29. Simoens S (2011) Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 3:29-36
30. Schneider CK, Vleminckx C, Gravanis I et al (2012) Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 30: 1179-1185
31. Guideline on good pharmacovigilance practices (GVP): module V - risk management systems. London, United Kingdom: Heads of Medicines Agencies, European Medicines Agency, 2012
32. World Health Organization (2006) WHO informal consultation on international nonproprietary names (INN) policy for biosimilar products. World Health Organization, Geneva
33. Medicines and Healthcare Products Regulatory Agency (2008) Biosimilar products. Drug Saf Updat 1:8
34. The Association of the British Pharmaceuticals Industry (2013) ABPI position on biosimilar medicines. The Association of the British Pharmaceuticals Industry, London
35. MabThera® (rituximab) [package insert] (2013) Roche Registration Limited, Welwyn Garden
36. Avastin® (bevacizumab) [package insert] (2013) Roche Registration Limited, Welwyn Garden
37. Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411-419 (Pubitemid 351325660)
38. Ebbers HC, Crow SA, Vulto AG, Schellekens H (2012) Interchangeability, immunogenicity, and biosimilars. Nat Biotechnol 30:1186-1190
39. Niederwieser D, Schmitz S (2011) Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 86:277-288